Celcuity Inc.
- CELC
- NASDAQ
- Biotechnology
- Cancer Diagnostics (CELx)
- Biomarker Testing
$57.12
Today +0.95%Quote Oct 19, 2026, 08:00 PM UTC
−33.36%over the last month
Max drawdown −33.4%From 1-month high −33.4%3 months −35.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Celcuity
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
155
Market value
$2.79B
Quote Oct 19
Floor
$56.09
1.8% below price
Resistance
$62.02
8.6% above price
Price vs analyst targets
12 analysts
Lowest target
$140.00Highest target
$178.00
$140.00Highest target
$178.00
- Price $57.12
- Average target $159.88
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 180% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CELCPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free